Retatrutide vs Semaglutide vs Tirzepatide: How the Incretin Research Peptides Differ

The defining difference between these three incretin research peptides is how many hormone receptors each one targets. Semaglutide is a single agonist that activates only the GLP-1 receptor. Tirzepatide is a dual agonist that activates both the GIP and GLP-1 receptors. Retatrutide is a triple agonist that activates the GIP, GLP-1, and glucagon receptors. That stepwise increase in receptor coverage — one, then two, then three targets — is the cleanest way to understand how the molecules relate to one another in the published literature.

Research-use-only note: this article compares receptor pharmacology and published experimental models. Bolt Peptide materials are supplied strictly for controlled in-vitro laboratory research by qualified professionals and are not for human or veterinary use.

Quick comparison

The research materials offered here are RUO chemicals supplied for laboratory study and are distinct from any approved product.

Semaglutide (single agonist)

Semaglutide is a GLP-1 receptor agonist that engages a single incretin receptor. Published literature characterizes its receptor pharmacology and metabolic research endpoints [2]. For more, see the semaglutide research overview.

Tirzepatide (dual agonist)

Tirzepatide adds a second target. It is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. The idea studied in the literature is that activating GIP alongside GLP-1 may act in combination rather than relying on GLP-1 alone. The SURMOUNT-1 trial evaluated tirzepatide over 72 weeks in adults with obesity [3]. Learn more in our full article, and compare the two directly in Semaglutide vs Tirzepatide.

Retatrutide (triple agonist)

Retatrutide extends the concept to a third receptor. It is a triple agonist of the GIP, GLP-1, and glucagon receptors — the glucagon component is what distinguishes it from tirzepatide. Because it is investigational and not approved, it exists today only as a research compound. A phase 2 trial published in the New England Journal of Medicine studied retatrutide in adults with obesity over 48 weeks [1]. See our full article for more.

Key differences studied in research

• Receptor count. The core distinction is mechanistic: one receptor (semaglutide), two receptors (tirzepatide), three receptors (retatrutide). Each step adds a hormone pathway to the molecule’s activity.
• The added pathways. Tirzepatide layers GIP-receptor activity onto GLP-1. Retatrutide layers both GIP and glucagon-receptor activity onto GLP-1 — the glucagon component is unique among the three.
• Published comparative findings. The cited studies report prespecified metabolic and imaging endpoints across controlled research models [1][2][3]. These citations document the scientific record and are not use guidance or claims for any Bolt material.
• Reported adverse events. Across the trials, the most commonly reported adverse events were gastrointestinal (such as nausea, vomiting, and diarrhea), described in the literature as consistent with the incretin-agonist class [1].

Research status and safety

The three compounds differ in receptor targets and status within the published research record. Bolt Peptide materials are research-use-only reference chemicals intended exclusively for controlled in-vitro laboratory investigation by qualified personnel. They are not finished commercial products and are not for human or veterinary use.

Handling

These reference materials are supplied in lyophilized form. Qualified personnel must establish solvent compatibility, material handling, and final concentration under an approved protocol and SOP. See the laboratory concentration and handling reference and browse related GLP research materials.

FAQ

What is the single biggest difference between the three? Receptor count. Semaglutide targets one receptor (GLP-1), tirzepatide targets two (GIP and GLP-1), and retatrutide targets three (GIP, GLP-1, and glucagon). The glucagon receptor is the target unique to retatrutide.

Are these finished commercial products? No. Bolt Peptide supplies research-use-only reference chemicals for controlled laboratory study.

Which one is “best”? That question does not apply to research materials. We make no efficacy, weight-loss, or appetite claims. The trials cited below report their own outcomes; this article only summarizes how the molecules differ by mechanism.

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023.
2. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.
3. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.

For research use only. Not for human or veterinary use. The research materials are not the approved/investigational medicines. Statements have not been evaluated by the FDA.